Osimertinib regressed an EGFR-mutant lung-adenocarcinoma bone-metastasis mouse model and increased long-term survival

Osimertinib regressed an EGFR-mutant lung-adenocarcinoma bone-metastasis mouse model and increased long-term survival

Bone is one of the most frequent metastatic sites in non-small cell lung cancer (NSCLC). Osimertinib, with and without bevacizumab (BV), has been investigated on advanced NSCLC patients. However, the efficacy of those drugs on bone metastasis of NSCLC has not been investigated. The human NSCLC cell...

Full description

Bibliographic Details
Main Authors: Takashi Higuchi, Norihiko Sugisawa, Jun Ho Park, Yu Sun, Guangwei Zhu, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Kentaro Igarashi, Michael Bouvet, Shree Ram Singh, Hiroyuki Tsuchiya, Robert M. Hoffman
Format: Article
Language:English
Published: Elsevier 2020-10-01
Series:Translational Oncology
Subjects:
Osimertinib
Non-small-cell lung carcinoma
Bone metastasis
Orthotopic mouse model
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523320303181

Internet

http://www.sciencedirect.com/science/article/pii/S1936523320303181

Similar Items